Status: Recruiting
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine
The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).
Participants needed: 40
Trial details
Phase: Phase 2Age: 18-55Biological sex: AllType: InterventionalSponsor: Clear Scientific, Inc.Updated: Jan 12, 2026Locations: 1
Eligibility criteria
Healthy participants aged 18 to 55 years, inclusive; [+6]
Estimated glomerular filtration rate <60 mL/min/1.73 m2; [+3]